Unlock instant, AI-driven research and patent intelligence for your innovation.

GLP-1 derivatives II

a technology of glucagonlike peptide and derivatives, which is applied in the field of new glucagonlike peptide derivatives of human glucagonlike peptides, can solve the problems of inconvenient high clearance of therapeutic agents, inability to be widely applied, and ineffectiveness of gip in niddm, and achieve strong synergistic effect and additional therapeutic advantages

Inactive Publication Date: 2008-05-01
NOVO NORDISK AS
View PDF3 Cites 0 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Benefits of technology

The modified GLP-1 derivatives exhibit a prolonged action and reduced clearance, enhancing their therapeutic potential for treating diabetes and obesity by maintaining effective blood levels and improving glycemic control with fewer administrations.

Problems solved by technology

A high clearance of a therapeutic agent is inconvenient in cases where it is desired to maintain a high blood level thereof over a prolonged period of time since repeated administrations will then be necessary.
In some cases it is possible to influence the release profile of peptides by applying suitable pharmaceutical compositions, but this approach has various shortcomings and is not generally applicable.
Furthermore, as an insulinotropic hormone, GIP was found to be almost ineffective in NIDDM (2).
However, the high clearance limits the usefulness of these compounds, and thus there still is a need for improvements in this field.

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Examples

Experimental program
Comparison scheme
Effect test

example 1

Synthesis of Nα-hexadecanoyl-Glu(ONSu)-OBut

[0240]To a suspension of H-Glu(OH)—OBut (4.2 g, 20.6 mmol), DMF (500 ml) and EDPA (2.65 g, 20.6 mmol) was added drop by drop a solution of Pal-ONSu (7.3 g, 20.6 mmol) in DMF (100 ml). The reaction mixture was stirred for 64 h at room temperature and then concentrated in vacuo to a total volume of 20 ml. The residue was partitioned between 10% aqueous citric acid (300 ml) and ethyl acetate (250 ml), and the phases were separated. The organic phase was concentrated in vacuo and the residue dissolved in DMF (50 ml). The resulting solution was added drop by drop to a 10% aqueous solution of citric acid (500 ml) kept at 0° C. The precipitated compound was collected and washed with iced water and dried in a vacuum drying oven. The dried compound was dissolved in DMF (45 ml) and HONSu (2.15 g, 18.7 mmol) was added. To the resulting mixture was added a solution of N,N′-dicyclohexylcarbodiimide (3.5 g, 17 mmol) in dichloromethane (67 ml). The react...

example 2

Synthesis of Nα-octadecanoyl-Glu(ONSu)-OBut

[0241]To a suspension of H-Glu(OH)—OBut(2.82 g, 13.9 mmol), DMF (370 ml) and EDPA (1.79 g, 13.9 mmol) was added drop by drop a solution of Ste-ONSu (5.3 g, 13.9 mmol) in DMF (60 ml). Dichloromethane (35 ml) was added, and the reaction mixture was stirred for 24 h at room temperature and then concentrated in vacuo. The residue was partitioned between 10% aqueous citric acid (330 ml) and ethyl acetate (200 ml), and the phases were separated. The organic phase was concentrated in vacuo and the residue dissolved in DMF (60 ml). The resulting solution was added drop by drop to a 10% aqueous solution of citric acid (400 ml) kept at 0° C. The precipitated compound was collected and washed with iced water and dried in a vacuum drying oven. The dried compound was dissolved in DMF (40 ml) and HONSu (1.63 g, 14.2 mmol) was added. To the resulting mixture was added a solution of DCC (2.66 g, 12.9 mmol) in dichloromethane (51 ml). The reaction mixture ...

example 3

Synthesis of Arg26,34, Lys36 (Nε-(γ-glutamyl(Nα-hexadecanoyl))) GLP-1 (7-36)-OH

[0242]To a mixture of Arg26,34, Lys36 GLP-1 (7-36)-OH (12.2 mg, 3.67 μmol), EDPA (13.3 mg, 103 μmol), NMP (1.71 ml) and water (855 μl) was added a solution of Pal-Glu(ONSu)-OBut (5.94 mg, 11 μmol), prepared as described above, in NMP (148 μl). The reaction mixture was gently shaken for 5 min. at room temperature, and then allowed to stand for an additional 90 min. at room temperature. The reaction was quenched by the addition of a solution of glycine (6 mg, 81 μmol) in water (0.6 ml). A 0.5% aqueous solution of ammonium-acetate (38 ml) was added, and the resulting mixture eluted onto a Varian 5 g C8 Mega Bond Elut®, the immobilised compound washed with 5% aqueous acetonitril (20 ml), and finally liberated from the cartridge by elution with TFA (25 ml). The eluate was concentrated in vacuo, and the residue purified by column chromatography using a cyanopropyl column (Zorbax 300SB-CN) and a standard acetoni...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

PropertyMeasurementUnit
acceleration voltageaaaaaaaaaa
volumeaaaaaaaaaa
pHaaaaaaaaaa
Login to View More

Abstract

The present invention relates to a derivative of GLP-1(7-C), wherein C is 35 or 36 which derivative has just one lipophilic substituent which is attached to the C-terminal amino acid residue.

Description

CROSS REFERENCE TO RELATED APPLICATIONS[0001]This application is a continuation of PCT / DK99 / 00086 filed Feb. 24, 1999 which claims priority under 35 U.S.C. 119 of Danish application 0274 / 98 filed Feb. 27, 1998 and of U.S. Provisional application 60 / 084,357 filed May 5, 1998, the contents of which are fully incorporated herein by reference.FIELD OF THE INVENTION[0002]The present invention relates to novel derivatives of human glucagon-like peptide-1 (GLP-1) and fragments thereof and analogues of such fragments which have a protracted profile of action and to methods of making and using them. The invention furthermore relates to novel derivatives of exendin and the uses of such derivatives.BACKGROUND OF THE INVENTION[0003]Peptides are widely used in medical practice, and since they can be produced by recombinant DNA technology it can be expected that their importance will increase also in the years to come. When native peptides or analogues thereof are used in therapy it is generally ...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
Patent Type & Authority Applications(United States)
IPC IPC(8): A61K38/00C07K7/00A61P3/10A61K38/26A61K38/28C07K14/605
CPCA61K38/26A61K38/28C07K14/57563C07K14/605A61K2300/00A61P3/10
Inventor KNUDSEN, LISELOTTE BJERREHUUSFELDT, PER OLAFNIELSEN, PER FRANKLINMADSEN, KJELD
Owner NOVO NORDISK AS